PRKDC and cancer: In a study by Zhang et al. (2023), comprehensive dose-response screening of DDR inhibitors with other anti-cancer therapeutics showed that various MTAs in combination with either ATM, ATR, or DNA-PK inhibitors have the greatest efficacy across 62 different cancer cell lines [171].